Elan’s Alzheimer’s Drug Candidate Misses the Mark

The inability of the medication to meet primary endpoints casts a doubt on Elan’s Alzheimer’s research platform

Karen Andersen, CFA 11 August, 2010 | 5:35PM
Facebook Twitter LinkedIn

Elan and partner Transition Therapeutics have announced that Phase II Alzheimer's drug candidate ELND005 did not meet cognitive and functional endpoints in an 18-month study. While our sales forecast for this drug is too small to drive our fair value estimate of Elan, we're concerned about the study's implications for the amyloid-beta theory of the disease, and we think detailed data (to be published at a later date) could give more insight into the potential of Elan's Alzheimer's research platform. The fact that the study did not meet its primary endpoints was not a surprise; the Phase II study was small (351 patients), and two of the three dose groups for ELND005 were discontinued in December due to a higher number of serious adverse events, including nine deaths among roughly 180 patients. Serious adverse events were also elevated in the low-dose group, at 21.6% of patients versus 13.3% in the placebo arm. Elan did see a biological effect on amyloid beta in the cerebrospinal fluid of a subset of patients (only 20 patients in the placebo and low-dose groups provided samples), but management is not willing to disclose prior to the study's publication whether there was a trend toward better cognition and function in the low-dose group. Elan and Transition plan to move the drug into a Phase III trial and simultaneously begin searching for another partner to further spread out the risk and reward. As an oral Alzheimer's drug candidate, ELND005 could tap into multi-billion-dollar potential if successful, but we're not boosting our 30% probability of approval or our sales estimates based on this mediocre top-line Phase II data.

Elan also announced that it no longer plans to sell Elan Drug Technologies, as market conditions would prevent the firm from obtaining a fair value for the asset. However, Elan still hopes to move forward with reducing its debt levels; by repurchasing $300 million in 2011 debt and refinancing $190 million of 2013 debt, Elan plans to reduce its total debt to $1.24 billion and extend its maturity. Given the recent $206 million legal settlement reserve and Elan's failure to shore up some additional liquidity by selling Elan Drug Technologies, we're considering lowering our credit rating for Elan.

 

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Karen Andersen, CFA  Karen Andersen, CFA, is a senior stock analyst with Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures